Kornimate/medical-research-clean huggingface dataset:
safety and effectiveness of adding saquinavir (fortovase) in soft gel capsule form to an anti-hiv drug combination in hiv-infected patients

Conditions: HIV Infections

Summary: the purpose of this study is to see if it is safe and effective to give saquinavir (as a soft gel capsule taken by mouth) along with 2 other anti-hiv drugs to hiv-infected patients.

prior to initiation of study treatment all patients are screened and baseline lab values are taken. patients then receive the study treatment, fortovase, two times a day plus 2 new nrti's. assessments will be performed at specified intervals throughout the duration of treatment.

Eligibility criteria:
inclusion criteria you may be eligible for this study if you: * are hiv-positive. * have an hiv count of 5,000 copies/ml or more. * have a cd4 count of 100 cells/mm3 or more. * meet specific requirements if you have ever taken nrtis. * are 16 - 64 years old (need consent if under 18). * agree to use effective methods of birth control during the study. exclusion criteria you will not be eligible for this study if you: * have taken non-nucleoside reverse transcriptase inhibitors (nnrtis) or protease inhibitors (pis) for more than 2 weeks. * have taken all the available nrtis. * have certain serious medical conditions, including severe liver disease or active opportunistic (aids-related) infection. * have a history of weight loss, muscle pain, and loss of appetite. * have taken certain medications, including anti-hiv drugs other than those required by this study. * are pregnant or breast-feeding. * abuse alcohol or drugs. * are unable to complete the study for any reason.

Keywords: drug therapy, combination hiv protease inhibitors dosage forms saquinavir reverse transcriptase inhibitors anti-hiv agents
bowen technique and post isometric relaxation in knee osteoarthritis patients

Conditions: Knee Osteoarthritis

Summary: the hamstring muscles are present at the posterior surface of the thigh. the muscles start in the gluteal region and run back of the thigh and insert into the popliteal fossa. the function of hamstring muscles flexes the knee and extension of the thigh. in degenerative joint disease, muscles tightness of the lower extremity leads to a decrease in joint flexibility. in knee joint osteoarthritis, hamstring muscles are more prone to tightness. the objective of this study is to compare the effects of the bowen technique and post isometric relaxation on pain, range of motion, and hamstring flexibility in knee osteoarthritis patients.

this study will be a randomized clinical trial and will be conducted at al- mustafa medical and physiotherapy center. the study will be completed within the time duration of six months. for data collection, a convenient sampling technique will be used. the population will be diagnosed with osteoarthritis patients. a sample size of total 24 patients will be taken in this study. the measurement tool will be active knee extension test, goniometer and numeric pain rating scale. the pre-test and post-test outcome measurement will be taken. patients will be divided into two groups. group a will receive the bowen technique intervention and group b will receive the post isometric relaxation technique. the interventions groups will receive three sessions per week for 4 weeks.

Eligibility criteria:
inclusion criteria: * symptomatic subjects with hamstring tightness * both male and female * age between 45 to 65 * o degree to 20-degree active knee extension loss * subject with inter-articular knee joint pathology * diagnosed osteoarthritis patients * grade 1 to 4 osteoarthritis exclusion criteria: * subject history of lower extremity injury * any neurological symptoms or radiating pain * any lower limb deformity * any fracture or surgery is done for knee

Keywords: post isometric relaxation bowen technique hamstring muscle flexibility knee osteoarthritis
tdcs and speech therapy for motor speech disorders caused by ftld syndromes: a feasibility study

Conditions: Nonfluent Aphasia, Progressive; Primary Progressive Nonfluent Aphasia; Primary Progressive Non Fluent Aphasia; Progressive Supranuclear Palsy; Corticobasal Degeneration; Behavioral Variant of Frontotemporal Dementia

Summary: the investigators will test the feasibility of using transcranial direct current stimulation (tdcs) and speech therapy to treat participants with motor speech disorders caused by frontotemporal lobar degeneration pathology including nonfluent variant primary progressive aphasia, progressive supranuclear palsy, corticobasal syndrome, or behavioral variant frontotemporal dementia. the investigators will deliver transcranial direct current stimulation (tdcs) either in a clinic setting at the university of california san francisco, or in patients' homes, via a consumer tdcs device and videoconferencing. transcranial direct current stimulation (tdcs) is a neuromodulation technique that can enhance the benefits of speech therapy treatment. participants will receive a dose of tdcs stimulation + speech therapy and a dose of sham tdcs + speech therapy in a randomized double blind crossover study performed either in the clinic or at home via videoconferencing. this study can be performed entirely remotely.


Eligibility criteria:
inclusion criteria: * mini mental status exam score \> 10 * diagnosis of nfvppa via gorno-tempini 2011 criteria, or a diagnosis of ftld syndrome including progressive supranuclear palsy, corticobasal syndrome or behavioral variant frontotemporal dementia plus a motor speech disorder (apraxia of speech and/or dysarthria) * able to give consent * right-handed * native english speaker * having a caregiver who is also able to sign and understand the caregiver's consent form. exclusion criteria: history of: * stroke * tbi * brain cancer * seizures * craniotomy, skull surgery or fracture * metallic implant in head * pacemaker or cardioverter-defibrillator * pregnancy.

Keywords: motor speech disorders dysarthria apraxia of speech
screening and management of hyperuricemia in patients with chronic medical diseases in assiut university hospital

Conditions: Hyperuricemia

Summary: in this study, we aimed to evaluate patients with chronic medical diseases in assiut university hospitals for -detection of asymptomatic hyperuricemia . * early identification of associated comorbidities . * management of indicated hyperurecimia .

hyperuricemia is classically defined as a serum uric acid (sua) of more than 7.0 mg/dl in men or more than 6.0 mg/dl in women . asymptomatic hyperuricemia is a condition, where patients have elevated levels of sua, yet do not exhibit symptoms or signs of monosodium urate crystal deposition, such as gout attacks, urolithiasis, or uric acid nephropathy . sua can be elevated 10 to 15 years before clinical manifestations of gout . up to 21% of the general population and 25% of hospitalized patients are estimated to have asymptomatic hyperuricemia . uric acid excretion mostly occurs via the kidneys, so decreased glomerular filtration rates in chronic kidney (ckd) patients contribute to the population increase in hyperuricemia. conversely, studies suggest that hyperuricemia may contribute to ckd , raising the possibility that urate-lowering therapies (ults) could be useful in slowing ckd progression . there was no independent association between hyperuricemia and systemic arterial hypertension. also, hyperuricemia has been reported as an independent risk factor for both coronary artery disease, congestive heart failure and diabetes mellitus. so efforts should be made to recognize individuals at risk of hyperuricemia by evaluating dietary habits, family history, and lifestyle factors, and regularly monitor sua levels. as well as, management strategies, including lifestyle modifications, pharmacotherapy, and dietary interventions, to effectively control sua and reduce the risk of associated complications.

Eligibility criteria:
inclusion criteria: * patients 18 years of age or older who were diagnosed with chronic medical diseases as diabetes mellitus , hypertension , obesity , metabolic syndrome , chronic kidney disease and cardiovascular disease (ischemic cardiomyopathy, heart failure ,coronary arteries disease) . exclusion criteria: * patients under the age of 18. * patients kown to have gouty arthritis * patients with acute kidney disease . * patients receiving thiazide diuretics. * patients with tumour lysis syndrome .
a clinical study of hrs-6209 in combination with letrozole in patients with breast cancer

Conditions: Breast Cancer

Summary: this is a study to evaluate the safety, tolerability, and pharmacokinetic characteristics of hrs-6209 combined with letrozole in breast cancer patients, and preliminarily observe its anti-tumor efficacy.


Eligibility criteria:
inclusion criteria: 1. women aged 18-75 years. 2. ecog performance status 0-1. 3. menopausal status. 4. evidence of radiographic disease progression during or after the last systemic anti-tumor therapy prior to the first study drug administration. 5. at baseline, there must be at least one measurable, extracranial lesion that meets recist v1.1 criteria. 6. expected survival \> 3 months. 7. women of childbearing potential must agree to use highly effective contraceptive measures during the study treatment and for 6 months after the end of treatment. women of childbearing potential must have a negative serum hcg test within 7 days prior to study enrollment and must not be breastfeeding. 8. voluntarily agree to participate in this clinical trial, willing and able to comply with the study visits and procedures, understand the study procedures, and have signed the informed consent form. exclusion criteria: 1. symptomatic visceral metastasis and other conditions, and the researcher judged that endocrine therapy was not suitable for use. 2. history of clinically serious cardiovascular disease. 3. the ecg examination was abnormal. 4. patients with clinically significant endometrial abnormalities, including but not limited to endometrial hyperplasia and dysfunctional uterine bleeding. 5. the subjects were in acute infection or active tuberculosis and needed drug treatment. 6. the patients received surgery, chemotherapy, immunotherapy and macromolecular targeted therapy within 4 weeks before the first medication. 7. pregnant and lactating women, or intending to become pregnant during the study. 8. there was a clear history of neurological or mental disorders and the subjects had a history of psychotropic drug abuse or drug abuse. 9. in the course of this study, it is expected to receive other anti-tumor treatments or drugs.
f-18 pet bone scans versus tc-99m bone scans for the diagnosis of bone metastases

Conditions: Cancer; Bone Metastases

Summary: the purpose of this study is to compare 18f-fluoride pet bone scans to traditional 99mtc-mdp bone scan to determine if one is better for diagnosing bone metastases.

compare the diagnostic sensitivity, specificity, and accuracy of 18f-fluoride pet bone scans versus traditional 99mtc-mdp bone scans for detecting bone metastases. determine if there is a significant change in clinical management between the two types of scans. measure and compare the number of equivocal or uncertain findings that would have caused additional testing, particularly additional imaging studies, to be performed for confirmation when using 18f-fluoride pet bone scans versus 99mtc-mdp bone scans. to quantify any adverse events resulting from either scan. to perform subgroup analyses according to cancer cell type.

Eligibility criteria:
inclusion criteria: * patient has cancer * has been referred for evaluation of bone metastases * patient or patient's legal representative can understand and consent to enrollment in the study * must be 18 years or older * can remain still during the scan (approximately one hour) * patient has medicare exclusion criteria: * patient does not have medicare * under the age of 18 * cannot lie still for the necessary time

Keywords: cancer bone metastases
implementation of gold standard ems cpr programs for 2% improvement in survival rates of out-of-hospital cardiac arrest in a metropolitan city

Conditions: Out-of-Hospital Cardiac Arrest

Summary: this study aims to improve the survival rate of out-of-hospital cardiac arrest patients by 2% through a bundle of three intervention measures including: 1) dispatcher-assisted cpr, 2) multi-tiered response team cpr, and 3) feedback cpr.

the project aims to implement gold standard emergency medical services (ems) cardiopulmonary resuscitation (cpr) programs, which will result in increased bystander cpr, reduced ems response time, and high quality cpr during prehospital resuscitation through a bundled approach including 1) dispatcher-assisted cpr (da-cpr), 2) multi-tiered response team cpr, and 3) feedback cpr. the da-cpr program aims to contribute to improved bystander cpr rate and reduced ems response time interval through rigorous monitoring of cardiac arrest detection at primary call receiving stage as well as increased number of dispatcher-assisted cpr instruction initiation in the target time of 90 seconds. the team cpr protocol will render synergetic efforts among participating ems personnel from both basic life support (bls) and advanced life support (als) units within the new tiered dispatch system and subsequently deliver uninterrupted cpr to out-of-hospital cardiac arrest (ohca) patients before hospital arrival. the feedback cpr monitoring and quality assurance program will contribute to high quality cpr delivered to the patients on the scene as well as during transport.

Eligibility criteria:
inclusion criteria: * ems-assessed ohca * cardiac etiology * above 15 years of age exclusion criteria: * patients who do not receive ems resuscitation * patients with signs of evident death (decapitation, evident livor mortis or rigor mortis) * do-not-resuscitate cases * pregnant patients * patients whom the mechanical devices cannot be applied to

Keywords: cardiopulmonary resuscitation emergency medicine
dc-cik in combination with chemotherapy ( gio / oxaliplatin or cisplatin ) versus first-line chemotherapy for locally advanced unresectable or metastatic gastric adenocarcinoma randomized controlled phase ii clinical study of treatment

Conditions: Gastric Cancer

Summary: this study evaluates the therapeutic effects of autologous dendritic cells co-cultured with cytokine-induced killer cells (dc-cik) combined with s-1 ((tegafur, gimeracil, and oteracil potassium) and oxaliplatin adjuvant chemotherapy in locally advanced unresectable or metastaticgastric cancer. half of participants will receive dc-cik combined with s-1 and oxaliplatin adjuvant chemotherapy,while the other half will receive s-1 and oxaliplatin adjuvant chemotherapy served as controls.


Eligibility criteria:
inclusion criteria: 1. age\>18y; 2. ecog physical status 0-1; 3. the histologic diagnosis of stomach/gastroesophageal junction adenocarcinoma; 4. according to the recist 1.1 standard with measurable or evaluable lesion; 5. accept swallow oral drug; 6. wbc≧4.0×10\^9/l;alc≧0.8×10\^9/l;anc≧1.5×10\^9/l;plt≧100×10\^9/l;alt,ast≦2.5 times of the normal limit;alp≦2.5 times of the normal limit;tbil﹤1.5 times of the normal limit;scr﹤1 times of the normal limit;alb≧30g/l; 7. the expected survival time of more than 3 months; 8. good compliance; 9. provide written informed consent. exclusion criteria: 1. vital organs (heart,liver,kidney) function is serious dysfunction; 2. patients received organ transplantation; 3. patients with other malignant tumors or have occurred brain metastasis; 4. patients with history of autoimmune disease; 5. patients in pregnancy or breast-feeding period(women of child-bearing age need to check pregnancy test); 6. patients with acute infection disease or in chronic active stage; 7. patients with clear history of drug allergy or belong to allergic constitution; 8. patients received chemotherapy,radiation therapy, immunosuppressive drugs (cyclosporine a,etc.) or other immune treatment in 4 weeks; 9. patients received other clinical trials in 4 weeks.
arousal analysis by pulse wave amplitude in patients with obstructive sleep apnea

Conditions: Obstructive Sleep Apnea

Summary: photoplethysmography is an easy non-invasive method to detect the pulse wave amplitude (pwa) from a finger. this can be measured using the somnocheck micro system. a pulse wave amplitude decrease (pwad) is considered to be a marker for autonomic activation. detecting the pwad is a surrogate marker for waking reactions (arousal) which eventually will contribute to assess sleep disruption and resulting performance deterioration. arousal and performance deterioration and its possible improvement under continuous positive airway pressure (cpap) therapy will be determined in this study.

patients from the sleep laboratory with verified obstructive sleep apnea syndrome (osas) will be asked to participate in this study. a device is used to determine autonomic arousal over night (somnocheck micro). the somnocheck micro records oxygen saturation as well as pulse frequency and breathing, and calculates an autonomic arousal index (aai). somnocheck measurements will take place in two nights (baseline and with cpap) and parallel to a standard polysomnography (psg). the psg provides data to analyze the arousal frequency according to asda rules, which will then be compared to the aai. performance is determined twice (prior and after cpap therapy) by the use of a steering simulator programme (dass). differences in arousal will be correlated with differences in performance (deviation from the road, reaction time). the subjects are also asked to fill out the epworth sleepiness scale (ess) twice, prior and after therapy. aim is to compare somnocheck and psg measurements and daytime sleepiness with dass and ess.

Eligibility criteria:
inclusion criteria: * obstructive sleep apnea (ahi \>5) exclusion criteria: * suspected acute cardiac, pulmonary or neurologic disease

Keywords: arousal detection pulse wave amplitude obstructive sleep apnea daytime sleepiness cardiorespiratory risk
acute pancreatitis and acute fluid collections

Conditions: Pancreatitis

Summary: the purpose of this study is to evaluate if percutaneous drainage of sterile fluid collections recurring after initial aspiration in acute pancreatitis yielded better results than their conservative management.


Eligibility criteria:
inclusion criteria: * symptoms and signs of acute pancreatitis and if pancreatic or/and peripancreatic fluid collections were confirmed by ultrasound and computed tomography examination exclusion criteria: * collections resulting from pancreatic surgery, chronic pancreatitis and encapsulated collections and collections with uncertainty about the relationship between the collections and clinical symptoms and signs of acute pancreatitis were excluded.

Keywords: conversion to more aggressive treatment of recurrent fluid collection
liquid biopsy in hepatocellular carcinoma

Conditions: Hepatic Carcinoma Malignant Primary Non-Resectable

Summary: circulating tumor dna (ctdna) carrying tumor-specific sequence alterations has been found in the cell-free fraction of blood. hepatocellular carcinoma (hcc) specimens are difficult to obtain, and noninvasive methods are required to assess cancer progression and characterize underlying genomic features. use of 'liquid biopsy' by assessing circulating cell free dna enables the clinician to offer targeted immunotherapy or signaling pathway inhibitors. it also offers a model to prove response to locoregional or immunotherapy therapy and predict tumor recurrence non-invasively.

novelty: mutation analysis may not only help identify cancer drivers, but they can also provide useful data to predict response to other treatment modalities such as immunotherapies, particularly immune checkpoint blockade. there is published data on liquid biopsy in india from oncology in the field of pulmonary and renal cancers, but these studies have not been done in cirrhosis or in hcc patients. objectives in this project we hope to develop a biomarker panel which helps us prognosticate patients and tailor targeted therapy as per their genetic mutation landscape. the treatment options for advanced hcc are limited, and tissue biopsy is not routinely performed. methods in this pilot project, we will analyze 30 patients with unresectable hepatocellular carcinoma, ineligible for liver transplantation, who will undergo locoregional therapy in the form of transarterial chemoembolization (tace) or radioembolization (tare) for tissue diagnosis of tumor tissue dna and circulating tumor dna. we will design personalized assays targeting somatic rearrangements of each tumor to quantify serum ctdna. exome sequencing will be performed using cell-free dna and paired primary tumor tissue dna in order to create a non-invasive liquid biopsy for diagnosis and prognostication of hcc.

Eligibility criteria:
inclusion criteria: * hepatocellular carcinoma bclc stages b and c of all aetiology, unresectable * age 18-70 years of either sex exclusion criteria: * contemplating hepatic resection or olt * refractory ascites * severe coagulation disorders prior to the procedure (pti \<70% and platelet count \< 80,000/mm3) * hepato-renal syndrome * chronic kidney disease * acute decompensation like hepatic encephalopathy and variceal bleeding * any known malignancy other than hcc * life expectancy \< 6 months

Keywords: hepatocellular carcinoma cell free tumor dna liquid biopsy
modified hip capsular incision: an easier way to do hip capsulorrhaphy in developmental dysplasia of the hip (ddh)

Conditions: Developmental Hip Dysplasia

Summary: developmental dysplasia of the hip (ddh) is the commonest hip problem seen by pediatric orthopaedic surgeons (1). ddh refers to an abnormal configuration of, or relationship between, the femoral head and the acetabulum .principals of surgical treatment of ddh, however, always include reduction and stabilization. these principals could be applied by conservative or surgical means (2). goal of treatment options to obtain and maintain reduction without damaging femoral head. surgical stabilization might be required in cases with failed conservative treatment, residual dysplasia or older children with neglected ddh. surgical stabilization is generally achieved by a reduction into a near anatomical position and a complementary capsulorrhaphy (3). in the classic t-shaped capsular incision, the vertical branch parallel to the axis of the neck and the horizontal branch 5 mm from the iliac insertion of the capsule, from anterior and downward to posterior and upward. two flaps are thus obtained (4). it was noticed that doing capsulorrhaphy after head reduction is cumbersome with this technique because it needs shallow-curved needles while suturing in narrow field and sometimes the suture material gets avulsed from medial flab. a suggested technique by doing a modified incision to make re -suturing of the capsule easier with multiple stitches.

this modified incision to make re -suturing of the capsule easier with multiple stitches.

Eligibility criteria:
inclusion criteria: * age 1-7 years old * primary ddh exclusion criteria: * paralytic hip dx in cases of (cerebral palsy,meningomyelocele,neuropathy or myopathy) * recurrent cases of ddh

Keywords: ddh developmental hip dysplasia capsulorrhaphy